The federal government’s 340B program, which provides deeply discounted drugs to hospitals that serve low-income patients, continues to be a source of controversy for hospitals […]
For people taking tirzepatide specifically, there’s another gene in play: GIPR. Tirzepatide is a dual agonist, meaning it targets both the GLP-1 and GIP receptors. […]